Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-5wvtr Total loading time: 0 Render date: 2024-07-20T22:21:53.003Z Has data issue: false hasContentIssue false

Chapter 14 - Hematopoietic Growth Factors after Hematopoietic Cell Transplantation: Are They Useful?

from Section 4 - Early Post-Transplant Interval

Published online by Cambridge University Press:  24 May 2017

By
Jürgen Finke  and
Roland Mertelsmann
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 119 - 122
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Gisselbrecht, C, Prentice, HG, Bacigalupo, A, Biron, P, Milpied, N, Rubie, H, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994;343(8899):696–700.CrossRefGoogle ScholarPubMed
Stahel, RA, Jost, LM, Cerny, T, Pichert, G, Honegger, H, Tobler, A, et al. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12(9):1931–8.CrossRefGoogle ScholarPubMed
Klumpp, TR, Mangan, KF, Goldberg, SL, Pearlman, ES, Macdonald, JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol 1995;13(6):1323–7.CrossRefGoogle ScholarPubMed
Schmitz, N, Dreger, P, Zander, AR, Ehninger, G, Wandt, H, Fauser, AA, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995;15(2):261–6.Google ScholarPubMed
Linch, DC, Milligan, DW, Winfield, DA, Kelsey, SM, Johnson, SA, Littlewood, TJ, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997;99(4):933–8.CrossRefGoogle ScholarPubMed
Faucher, C, Le Corroller, AG, Chabannon, C, Novakovitch, G, Manonni, P, Moatti, JP, et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996;17(4):533–6.Google ScholarPubMed
Bolwell, BJ, Pohlman, B, Andresen, S, Kalaycio, M, Goormastic, M, Wise, K, et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998;21(4):369–73.CrossRefGoogle ScholarPubMed
Bence-Bruckler, I, Bredeson, C, Atkins, H, McDiarmid, S, Hamelin, L, Hopkins, H, et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998;22(10):965–9.CrossRefGoogle ScholarPubMed
Piccirillo, N, Sica, S, Laurenti, L, Chiusolo, P, La Barbera, EO, Sora, F, et al. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1999;23(12):1245–50.CrossRefGoogle ScholarPubMed
Martino, M, Pratico, G, Messina, G, Irrera, G, Massara, E, Messina, G, et al. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. Eur J Haematol 2006;77(5):410–5.CrossRefGoogle ScholarPubMed
Rifkin, R, Spitzer, G, Orloff, G, Mandanas, R, McGaughey, D, Zhan, F, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10(3):186–91.CrossRefGoogle ScholarPubMed
Gerds, A, Fox-Geiman, M, Dawravoo, K, Rodriguez, T, Toor, A, Smith, S, et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010;16(5):678–85.CrossRefGoogle ScholarPubMed
Sebban, C, Lefranc, A, Perrier, L, Moreau, P, Espinouse, D, Schmidt, A, et al. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer 2012;48(5):713–20.CrossRefGoogle ScholarPubMed
Schriber, JR, Chao, NJ, Long, GD, Negrin, RS, Tierney, DK, Kusnierz-Glaz, C, et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood 1994;84(5):1680–4.CrossRefGoogle ScholarPubMed
Locatelli, F, Pession, A, Zecca, M, Bonetti, F, Prete, L, Carra, AM, et al. Use of recombinant human granulocyte colony-stimulating factor in children given allogeneic bone marrow transplantation for acute or chronic leukemia. Bone Marrow Transplant 1996;17(1):31–7.Google ScholarPubMed
Hagglund, H, Ringden, O, Oman, S, Remberger, M, Carlens, S, Mattsson, J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1999;24(8):831–6.CrossRefGoogle ScholarPubMed
Bishop, MR, Tarantolo, SR, Geller, RB, Lynch, JC, Bierman, PJ, Pavletic, ZS, et al. A randomized, double-blind trial of filgrastim (granulocyte colony- stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000;96(1):80–5.CrossRefGoogle ScholarPubMed
Przepiorka, D, Smith, TL, Folloder, J, Anderlini, P, Chan, KW, Korbling, M, et al. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood 2001;97(11):3405–10.CrossRefGoogle ScholarPubMed
Ciernik, IF, Schanz, U, Gmur, J. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial. Bone Marrow Transplant 1999;24(2):147–51.CrossRefGoogle ScholarPubMed
Schwab, L, Goroncy, L, Palaniyandi, S, Gautam, S, Triantafyllopoulou, A, Mocsai, A, et al. Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. Nat Med 2014;20(6):648–54.CrossRefGoogle ScholarPubMed
Ringden, O, Labopin, M, Gorin, NC, Le Blanc, K, Rocha, V, Gluckman, E, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004;22(3):416–23.CrossRefGoogle Scholar
Ringden, O, Labopin, M, Gorin, NC, Volin, L, Torelli, GF, Attal, M, et al. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. Br J Haematol 2012;157(2):220–9.CrossRefGoogle ScholarPubMed
Volpi, I, Perruccio, K, Tosti, A, Capanni, M, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001;97(8):2514–21.CrossRefGoogle ScholarPubMed
Dekker, A, Bulley, S, Beyene, J, Dupuis, LL, Doyle, JJ, Sung, L. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. J Clin Oncol 2006;24(33):5207–15.CrossRefGoogle ScholarPubMed
Vannucchi, AM, Bosi, A, Ieri, A, Guidi, S, Saccardi, R, Lombardini, L, et al. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Bone Marrow Transplant 1996;17(4):527–31.Google ScholarPubMed
Chao, NJ, Schriber, JR, Long, GD, Negrin, RS, Catolico, M, Brown, BW, et al. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin’s and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Blood 1994;83(10):2823–8.CrossRefGoogle ScholarPubMed
Ballen, KK, Becker, PS, Yeap, BY, Matthews, B, Henry, DH, Ford, PA. Autologous stem-cell transplantation can be performed safely without the use of blood-product support. J Clin Oncol 2004;22(20):4087–94.CrossRefGoogle ScholarPubMed
Klaesson, S, Ringden, O, Ljungman, P, Lonnqvist, B, Wennberg, L. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high- dose erythropoietin. Bone Marrow Transplant 1994;13(4):397–402.Google ScholarPubMed
Link, H, Boogaerts, MA, Fauser, AA, Slavin, S, Reiffers, J, Gorin, NC, et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994;84(10):3327–35.CrossRefGoogle ScholarPubMed
Biggs, JC, Atkinson, KA, Booker, V, Concannon, A, Dart, GW, Dodds, A, et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group. Bone Marrow Transplant 1995;15(1):129–34.Google ScholarPubMed
Paltiel, O, Cournoyer, D, Rybka, W. Pure red cell aplasia following ABO-incompatible bone marrow transplantation: response to erythropoietin. Transfusion 1993;33(5):418–21.CrossRefGoogle ScholarPubMed
Fujisawa, S, Maruta, A, Sakai, R, Taguchi, J, Tomita, N, Ogawa, K, et al. Pure red cell aplasia after major ABO-incompatible bone marrow transplantation: two case reports of treatment with recombinant human erythropoietin. Transpl Int 1996;9(5):506–8.CrossRefGoogle ScholarPubMed
Gaya, A, Urbano-Ispizua, A, Fernandez-Aviles, F, Salamero, O, Roncero, JM, Rovira, M, et al. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Biol Blood Marrow Transplant 2008;14(8):880–7.CrossRefGoogle ScholarPubMed
Jaspers, A, Baron, F, Willems, E, et al. Erythropoietin therapy after allogeneic hematopoietic cell transplantation: a prospective, randomized trial. Blood. 2014;124(1):33–41.CrossRefGoogle ScholarPubMed
Bolwell, B, Vredenburgh, J, Overmoyer, B, Gilbert, C, Chap, L, Menchaca, DM, et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000;26(2):141–5.CrossRefGoogle ScholarPubMed
Cheng, G, Saleh, MN, Marcher, C, Vasey, S, Mayer, B, Aivado, M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011;377(9763):393–402.CrossRefGoogle Scholar
Molineux, G, Newland, A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010;150(1):9–20.CrossRefGoogle ScholarPubMed
Kuter, DJ. New thrombopoietic growth factors. Blood 2007;109(11):4607–16.CrossRefGoogle ScholarPubMed
Ruiz-Delgado, GJ, Lutz-Presno, J, Ruiz-Arguelles, GJ. Romiplostin may revert the thrombocytopenia in graft-versus-host disease. Hematology 2011;16(2):108–9.CrossRefGoogle ScholarPubMed
Reid, R, Bennett, JM, Becker, M, Chen, Y, Milner, L, Phillips, GL, et al. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia. Am J Hematol 2012;87(7):743–5.CrossRefGoogle ScholarPubMed
Liesveld, JL, Phillips, GL, Becker, M, Constine, LS, Friedberg, J, Andolina, JR, et al. A phase 1 trial of eltrombopag in patients undergoing stem cell transplantation after total body irradiation. Biol Blood Marrow Transplant 2013;19(12):1745–52.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×